Venglustat
- Generic Name
- Venglustat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24FN3O2S
- CAS Number
- 1401090-53-6
- Unique Ingredient Identifier
- BLP1XA3FZA
- Background
Venglustat is under investigation in clinical trial NCT01674036 (Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 8
- Registration Number
- NCT06421714
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
A Study of the Safety, Tolerability, and Bioequivalence of Orally Administered Venglustat in Healthy Adult Participants
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 65
- Registration Number
- NCT06418607
- Locations
- 🇺🇸
Prism Research Site Number : 8400002, Saint Paul, Minnesota, United States
🇺🇸Clinical Pharmacology of Miami Site Number : 8400001, Miami, Florida, United States
A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult Participants
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 9
- Registration Number
- NCT06418620
- Locations
- 🇺🇸
Prism Research Site Number : 8400001, Saint Paul, Minnesota, United States
Excretion Balance, Pharmacokinetics, and Metabolism Following of [14C]-Venglustat Administration in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 6
- Registration Number
- NCT05238714
- Locations
- 🇬🇧
Investigational Site Number :8260001, Nottingham, Nottinghamshire, United Kingdom
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
- Conditions
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 43
- Registration Number
- NCT05222906
- Locations
- 🇺🇸
Yale University School of Medicine - Investigational Site Number: 8400003, New Haven, Connecticut, United States
🇺🇸University of Iowa - Investigational Site Number: 8400002, Iowa City, Iowa, United States
🇺🇸Texas Oncology - Medical City Dallas Site Number : 8400008, Dallas, Texas, United States
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
- Conditions
- Interventions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 478
- Registration Number
- NCT03523728
- Locations
- 🇺🇸
Investigational Site Number 8400014, Iowa City, Iowa, United States
🇦🇺Investigational Site Number 0360003, Nedlands, Australia
🇨🇳Investigational Site Number 1560002, Hefei, China
Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 63
- Registration Number
- NCT01674036
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.